Allele-Selective Knockdown of MYH7 Using Antisense Oligonucleotides.

Area of Science:

• Cardiovascular Genetics
• Molecular Medicine
• Biochemistry

Background:

• Hypertrophic cardiomyopathy (HCM) is linked to numerous dominant-negative myosin mutations.
• The biomechanical consequences of these mutations are diverse, complicating treatment strategies.
• Myosin heavy chain 7 (MYH7) gene mutations are a significant cause of HCM.

Purpose of the Study:

• To investigate locked nucleic acid (LNA)-modified antisense oligonucleotides (ASOs) for selective knockdown of mutant MYH7 transcripts.
• To target single-nucleotide polymorphisms (SNPs) common in the MYH7 gene for allele-specific therapy.
• To assess the therapeutic feasibility of ASOs in a genetically diverse HCM population.

Main Methods:

• Identification of three common SNPs in the MYH7 gene.
• Design and screening of ASO libraries targeting reference and alternate MYH7 alleles.
• Validation of allele-selective ASO knockdown in vitro.
• Testing of ASOs in a humanized mouse model of HCM.

Main Results:

• Identification of ASOs capable of selectively knocking down either the reference or alternate MYH7 allele at all three targeted SNP regions.
• Demonstration of allele-selective transcript knockdown using ASOs in a relevant mouse model.
• Confirmation of the specificity and efficacy of SNP-targeting ASOs.

Conclusions:

• SNP-targeting ASOs represent a promising therapeutic strategy for HCM.
• This approach offers potential for personalized medicine in treating genetically heterogeneous cardiac diseases.
• ASO technology can be adapted to address specific genetic variations in MYH7-related HCM.